Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Other Non-Current Liabilities (2023 - 2025)

Telix Pharmaceuticals has reported Other Non-Current Liabilities over the past 3 years, most recently at $3.5 million for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 60.95% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, down 60.95% year-over-year, with the annual reading at $3.5 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities was $3.5 million for Q4 2025 at Telix Pharmaceuticals, down from $9.0 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $9.0 million in Q4 2024 and troughed at $3.5 million in Q4 2025.
  • The 3-year median for Other Non-Current Liabilities is $5.2 million (2023), against an average of $5.9 million.
  • Year-over-year, Other Non-Current Liabilities soared 72.85% in 2024 and then plummeted 60.95% in 2025.
  • A 3-year view of Other Non-Current Liabilities shows it stood at $5.2 million in 2023, then soared by 72.85% to $9.0 million in 2024, then plummeted by 60.95% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Other Non-Current Liabilities are $3.5 million (Q4 2025), $9.0 million (Q4 2024), and $5.2 million (Q4 2023).